EP Patent

EP0637586A1 — 2-(Piperidin-4-yl, pyridin-4-yl and tetrahydropyridin-4-yl)benzofuran-7-ol and carbamate derivatives, their preparation and their use as acetylcholinesterase inhibitors

Assigned to Aventis Pharmaceuticals Inc · Expires 1995-02-08 · 31y expired

What this patent protects

2-(piperidin-4-yl, pyridin-4-yl and tetrahydropyridin-4-yl)benzofuran-7-ol and carbamate derivatives of the formula I wherein R₁ is hydrogen, loweralkyl, arylloweralkyl, CONHR₅ or CONR₆R₇ R₂ is hydrogen, cyano, CH₂NR₈R₉, CONHR₅ or CONR₆R₇; R₃ is wher…

USPTO Abstract

2-(piperidin-4-yl, pyridin-4-yl and tetrahydropyridin-4-yl)benzofuran-7-ol and carbamate derivatives of the formula I wherein R₁ is hydrogen, loweralkyl, arylloweralkyl, CONHR₅ or CONR₆R₇ R₂ is hydrogen, cyano, CH₂NR₈R₉, CONHR₅ or CONR₆R₇; R₃ is where R₁₀ is hydrogen, loweralkyl, arylloweralkyl, CONHR₅, CONR₆R₇, acyl, acyloxyloweralkyl or acyloxyarylloweralkyl; R₄ is hydrogen, halogen, loweralkyl or loweralkoxy; R₅ is hydrogen, loweralkyl or arylloweralkyl; R₆ is loweralkyl or arylloweralkyl; R₇ is loweralkyl or arylloweralkyl; R₈ is hydrogen, loweralkyl, arylloweralkyl or acyl; R₉ is hydrogen, loweralkyl or arylloweralkyl; R₁₁ is loweralkyl, aryl or arylloweralkyl; with the proviso that if R₁ is hydrogen or loweralkyl, R₂ cannot be hydrogen; or a pharmaceutically acceptable acid addition salt thereof, or where applicable, an optical or geometric isomer or racemic mixture thereof, which are useful as acetylcholinesterase inhibitors and as such may be useful for the treatment of Alzheimer's disease and other senile dementias.

Drugs covered by this patent

Patent Metadata

Patent number
EP0637586A1
Jurisdiction
EP
Classification
Expires
1995-02-08
Drug substance claim
No
Drug product claim
No
Assignee
Aventis Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.